Minocycline in active rheumatoid arthritis
Article first published online: 9 DEC 2005
Copyright © 1994 American College of Rheumatology
Arthritis & Rheumatism
Volume 37, Issue 5, pages 629–636, May 1994
How to Cite
Kloppenburg, M., Breedveld, F. C., Terwiel, J. P. H., Mallee, C. and Dijkmans, B. A. C. (1994), Minocycline in active rheumatoid arthritis. Arthritis & Rheumatism, 37: 629–636. doi: 10.1002/art.1780370505
- Issue published online: 9 DEC 2005
- Article first published online: 9 DEC 2005
- Manuscript Accepted: 7 OCT 1993
- Manuscript Received: 14 JUN 1993
- Lederle Nederland
Objective. To determine the efficacy of minocycline in the treatment of rheumatoid arthritis (RA).
Methods. Minocycline (maximal oral daily dose 200 mg) or placebo was administered in a 26-week, randomized, double-blind study to 80 patients with active RA, who were treated or had previously been treated with at least one disease-modifying antirheumatic drug.
Results. There were 15 premature discontinuations: 6 (5 taking minocycline) because of adverse effects, 8 (all taking placebo) because of lack of efficacy, and 1 (taking placebo) because of intercurrent illness. There was a statistically significant improvement in the minocycline group over the placebo group. There was a pronounced improvement in laboratory parameters of disease activity; however, improvement in clinical parameters was less impressive. The observed adverse effects attributable to minocycline were mainly gastrointestinal symptoms and dizziness.
Conclusion. The results of the present study suggest that minocycline is beneficial and relatively safe in RA patients.